Business

Starbucks announced its quarterly earnings on Tuesday, surpassing analysts’ expectations for earnings per share. The company reported adjusted earnings per share of $1, compared to the expected 95 cents. However, despite this positive news, the coffee giant’s same-store sales fell short of Wall Street’s estimates. Starbucks recorded a net income attributable to the company of
The power duo of Warner Bros.’ “Barbie” and Universal’s “Oppenheimer” continues to dominate the global box office, surpassing the remarkable milestone of $1.1 billion in ticket sales since its release on July 21. Strong Second Week Performances Unlike typical blockbusters, “Barbenheimer” experienced a smaller-than-average drop in ticket sales during its second week, with only a
Macy’s, the well-established department store chain with a history spanning 165 years, is grappling with declining sales and a struggling stock amid a thriving market. In an effort to keep up with newer competitors such as direct-to-consumer brands, online giants like Amazon and Shein, and big-box players like Target, Macy’s is placing its bets on
UnitedHealth Group, the largest healthcare company in the United States, experienced a surge in stock prices after reporting impressive second-quarter revenue and adjusted earnings that surpassed Wall Street’s predictions. Despite concerns over rising medical costs and an increase in demand for non-urgent surgeries and outpatient services, the company managed to ease investor worries. UnitedHealth Group’s
In a strategic move to accelerate the development of artificial intelligence (AI) models for drug discovery, chipmaker Nvidia has announced its plan to invest $50 million in Recursion Pharmaceuticals. Following this announcement, Recursion’s stock experienced a significant surge of 80%, while Nvidia’s shares also rose by more than 2%. This investment aims to leverage Nvidia’s
Only approximately one-third of patients who are prescribed weight loss drugs, such as Wegovy, a popular injection developed by Novo Nordisk, continue taking the medication after a year. Surprisingly, the total healthcare costs for this group actually increased, according to an analysis conducted by Prime Therapeutics, a leading pharmacy benefit manager in the United States.